Nordic Nanovector and APIM to merge

10 November 2022

News of the planned merger of Norway-based companies Nordic Nanovector (OSE: NANOV) and APIM Therapeutics, a privately held, clinical-stage cancer-focused biotechnology firm, saw the former’s shares fall 13.3% to 1.17 Norwegian kroner by late afternoon.

Subject to completion of the agreement, which is expected to complete in the current quarter, Nordic Nanovector will purchase shares in APIM, and become the parent entity of APIM. The combined company – which will be renamed in due course – will be around 76% owned by APIM shareholders and 24% by Nordic Nanovector investors and will aim to retain its listing on the Oslo stock exchange.

The agreement follows the review that Nordic Nanovector conducted, in conjunction with Carnegie Investment Bank, to optimize shareholder value following its decision to discontinue the PARADIGME study for Nordic Nanovector's lead asset Betalutin (177Lu lilotomab satetraxetan) in third-line relapsed and anti-CD20 refractory follicular lymphoma. .

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK